A Functional Genomics Pipeline to Identify High-Value Asthma and Allergy CpGs in the

Human Methylome

Andréanne Morin, PhD[1,17], Emma E. Thompson, PhD[1,17], Britney A. Helling, PhD[1,17],

Lyndsey E. Shorey-Kendrick, PhD[2], Pieter Faber, PhD[3], Tebeb Gebretsadik, MPH[4],

Leonard B. Bacharier, MD[5], Meyer Kattan, MD[6], George T. O'Connor, MD[7], Katherine

Rivera-Spoljaric, MD[8], Robert A. Wood, MD[9], Kathleen C. Barnes, PhD[10], Rasika A.

Mathias, PhD[11], Matthew C. Altman, MD[12], Kasper Hansen, PhD[13], Cindy T. McEvoy, MD

[14], Eliot R. Spindel, MD[2], Tina Hartert, MD[4], Daniel J. Jackson, MD[15], James E. Gern, MD

[15], Chris G. McKennan, PhD[16,18,*], and Carole Ober, PhD[1,18,*] on behalf of program

collaborators for Environmental Influences on Child Health Outcomes and Children's

Respiratory and Environmental Workgroup

[1] Department of Human Genetics, University of Chicago, Chicago, IL 60637

[2] Division of Neuroscience, Oregon National Primate Research Center, Oregon Health

and Science University, Beaverton, OR 97006

[3] Genomics Core, University of Chicago, Chicago, IL 60637

[4] Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN

37232

[5] Department of Pediatrics, Monroe Carell Jr Children's Hospital at Vanderbilt University

Medical Center, Nashville, TN 37203

[6] Department of Pediatrics, Columbia University Medical Center, New York, NY 10032

[7] Pulmonary Center, Boston University School of Medicine, Boston, MA 02118

[8] Department of Pediatrics, Washington University, St. Louis, MO 63110

[9] Department of Pediatrics, Johns Hopkins University, Baltimore, MD 21287

[10] Department of Medicine, University of Colorado Denver, Aurora, CO 80045

[11] Department of Medicine, Johns Hopkins University, Baltimore, MD 21224

[12] Systems Immunology Division, Benaroya Research Institute Systems, Seattle, WA

98101; Department of Medicine, University of Washington, Seattle, WA 98195

[13] Department of Biostatistics, Bloomberg School of Public Health, Johns Hopkins

University, Baltimore, MD 21205

[14] Department of Pediatrics, Oregon Health and Science University, Portland, OR 97239

[15] Department of Pediatrics, University of Wisconsin School of Medicine and Public

Health, Madison, WI 53792-9988

[16] Department of Statistics, University of Pittsburgh, Pittsburgh, PA 15260

[17] A.M., E.E.T., and B.A.H. contributed equally to this work.

[18] C.M.K. and C.O. jointly supervised this work.

*Corresponding authors:

Carole Ober, PhD

Department of Human Genetics, University of Chicago

920 E. 58th St, Chicago, IL 60637

Tel: 773-834-0735

Email: c-ober@genetics.uchicago.edu

Christopher Gordon McKennan, PhD

Department of Statistics, University of Pittsburgh

1826 Wesley W. Posvar Hall

230 S Bouquet St, Pittsburgh, PA 15260

Tel: 412-624-8368

Email: CHM195@pitt.edu

The content is solely the responsibility of the authors and does not necessarily represent

the official views of the National Institutes of Health.

Grant Support: Research reported in this publication was supported by the

Environmental influences on Child Health Outcomes (ECHO) program, Office of The

Director, National Institutes of Health, under Award Numbers U2COD023375

(Coordinating Center), U24OD023382 (Data Analysis Center), U24OD023319 (PRO Core),

UH3 OD023282 (COAST, INSPIRE, URECA) and UH3 OD023288 (VCSIP); and grants UM1

AI114271, UM1 AI160040, U19 AI62310, U19 AI095227, UL1 TR002243 P51 OD011092

and R01 HL104608.

Disclosures: L.B.B. reports personal fees from GlaxoSmithKline Genentech/Novartis,

Merck, DBV Technologies, Teva, Boehringer Ingelheim, AstraZeneca,

WebMD/Medscape, Sanofi/Regeneron, Vectura, Circassia, Elsevier, Kinaset, and

Abstract

Background: DNA methylation of cytosines at CpG dinucleotides is a widespread epigenetic mark; but genome-wide variation has been relatively unexplored due to the limited representation of variable CpGs on commercial high-throughput arrays.

Objective: To explore this hidden portion of the epigenome, we combined whole-genome bisulfite sequencing (WGBS) with *in silico* evidence of gene regulatory regions to design a custom array of high-value CpGs. We focused these studies in airway epithelial cells from children with and without allergic asthma because these cells mediate the effects of inhaled microbes, pollution, and allergens on asthma and allergic disease risk.

Methods: We identified differentially methylated regions (DMRs) from WGBS in nasal epithelial cell (NEC) DNA from 39 children with and without allergic asthma of both European and African ancestries. We selected CpGs from DMRs, previous allergy or asthma Epigenome-Wide Association Studies (EWAS), or Genome-Wide Association Study (GWAS) loci, and overlapped them with functional annotations for inclusion on a custom Asthma&Allergy array. Using both the Custom and EPIC arrays, we performed EWAS of allergic sensitization (AS) in NEC DNA from children in the URECA birth cohort and using the Custom array in the INSPIRE birth cohort. We assigned each CpG on the arrays to its nearest gene and its promotor capture Hi-C interacting gene and performed expression quantitative trait methylation (eQTM) studies for both sets of genes.

Results: Custom array CpGs were enriched for intermediate methylation (IM) levels

compared to EPIC CpGs. IM CpGs were further enriched among those associated with AS

and for eQTMs on both arrays.

Conclusions: Our study revealed signature features of high-value CpGs and evidence for

epigenetic regulation of genes at AS EWAS loci that are robust to race/ethnicity,

ascertainment, age, and geography.

Clinical Implications: These studies identified allergic sensitization-associated

differentially methylated CpGs and their target genes in airway epithelium, providing

potential epigenetic mechanisms in the development of allergic diseases and suggesting

novel drug targets.

Capsule Summary: This study of previously unexplored regions of the airway epithelial

methylome revealed novel epigenetic mechanisms regulating genes previously

implicated in the pathogenesis of asthma and allergic diseases.

Key Words: EWAS, DNA methylation array, gene expression, airway epithelial cells

Abbreviations: **AS**, allergic sensitization; **DMC**, differentially methylated CpG;

DMR, differentially methylated region; **eQTM**, expression quantitative trait

methylation; **EWAS**, epigenome-wide association study; **FET**, fisher exact test;

GWAS, genome-wide association study; **IM**, intermediate methylation; **LF**, latent

factors; **NEC**, nasal epithelial cells; **PCA**, principal components analysis; **SPT**,

skin prick test; **WGBS**, whole-genome bisulfite sequencing.

Introduction

Epigenetics refers to modifications of DNA molecules that do not alter the DNA sequence but play important roles in regulating gene expression. Environmental exposures can directly modify epigenetic marks in the human genome[1], and epigenetic responses can mediate the effects of exposures on gene expression[2] and disease risk[3]. Thus, the epigenome may contribute directly to disease risk or be sites of gene-environment interactions, providing both complementary data and mechanistic insights, respectively, to genome-wide association studies (GWAS). The most common epigenetic mark in the human genome is methylated cytosines at CpG dinucleotides and the availability of high-throughput array-based platforms to measure DNA methylation has led to an explosion of epigenome-wide association studies (EWAS)[4]. The most used commercial array, the InfinityMethylationEPIC BeadChip (Illumina, Inc., San Diego, CA), interrogates up to 850,000 CpGs, but this comprises <5% of CpGs in the human genome. Because the selection of CpGs on the EPIC array was agnostic with respect to disease or tissue types, findings to date may represent just the tip of the iceberg with an abundance of yet unknown functional CpG sites contributing to disease risk.

The goal of our study was to develop and validate a custom Asthma&Allergy DNA methylation array enriched for CpGs in airway epithelial cells that are likely to be functional and associated with asthma and allergic diseases in populations of diverse ancestries. We focused on airway epithelial cells because of their critical role in responding to inhaled microbes, pollution and allergens and mediating their

135   downstream effects on asthma and allergic disease risk[5, 6]. An overview of our study

136   design is shown in **Fig. 1**.

Methods

Cohorts Included in Whole Genome Bisulfite Sequencing (WGBS) Studies or Epigenome-Wide Association Studies (EWAS)

Three longitudinal birth cohorts were included in these studies: the URban Environment and Childhood Asthma (URECA)[7] cohort (n=20) and the Childhood Origins of ASThma (COAST)[8] cohort (n=19) were included in the WGBS studies; URECA (n=280) and the Infant Susceptibility to Pulmonary Infections and Asthma Following RSV Exposure (INSPIRE)[9] (n=474) were included in EWAS of allergic sensitization (AS). All studies were approved by the Institutional Review Boards of each of the institutions recruiting subjects. For each cohort, one parent or guardian provided informed consent for their child's participation. Informed consent was obtained from participants in the COAST cohort after their 18th birthday. The characteristics of the 280 URECA and 474 INSPIRE participants in the EWAS are described in **Table I**; detailed descriptions of the three cohorts are included in the Online Repository.

Cohorts included in Cross-Tissue Comparison Studies

In addition to studying nasal epithelial cell DNA with the Asthma&Allergy Custom array in URECA, we included results from studies of the Custom array in DNA from nasal lavage cells (n=96), buccal cells (n=96), placenta (n=96) and cord blood (n=96). The nasal lavage cell DNA was isolated from URECA subjects at mean age 13.4 years (range = 12.8 - 14.9 years). The buccal, placenta and cord blood cell DNA was collected from

participants in the Vitamin C to Decrease the Effects of Smoking in Pregnancy on Infant

Lung Function (VCSIP) cohort[10].

Whole Genome Bisulfite Sequencing and DMR Studies

DNA (250 ng) from participants in the URECA and COAST cohorts was transferred to the

University of Chicago Genomics Core Facility. Bisulfite conversion and sequencing were

conducted using the EZ DNA Methylation-Gold Kit library prep and the Swift Biosciences

Accel-NGS Methyl-seq DNA library kit, respectively. Samples were sequenced to a

minimum of 330 million reads on the Illumina NovaSEQ6000 (S4 flowcell). Adapters

were removed from sequence reads using trimgalore[11] and then mapped using bismark

(version 0.18.2)[12] and the hg19 reference assembly. Bismark was also used to remove

duplicate reads and to call methylation values. Prior to differential methylated region

(DMR) analyses, CpGs were removed if they overlapped with a common single

nucleotide polymorphism (SNP) (minor allele frequency [MAF] >0.05) in 1000 genomes

CEU or YRI populations[13] or in Blacklisted regions[14]. Variant calling from WGBS was

performed using the biscuit algorithm, which also identified sample swaps and

contamination. The variant calls from WGBS were compared to either array-based

genotypes (COAST) or whole genome-sequence-based genotypes (URECA). All variant

calls matched with an accuracy of >95%. One sample in COAST was a duplicate and was

excluded from further analysis, leaving 19 samples for analysis (9 allergic asthmatics and

10 non-asthma/non-allergic controls). The DMR analyses are described in the Online

Repository.

Selection of CpGs and Design of the Custom Array

Our pipeline for selecting high-value CpGs for a custom array was implemented in three

steps (**Fig. E1** in this article's Online Repository). Additional details are described in the

Online Repository. Our goal was to develop a custom array with 50,000 probes for CpGs

that would complement and serve as a "booster" for the EPIC array in studies of asthma

and allergic diseases. Briefly, we first identified a set of CpGs based on prior evidence of

association with asthma or allergic diseases (atopic dermatitis/eczema, allergic

rhinitis/hay fever, and food allergy) from three categories of studies. The first category

included the 199,473 CpGs within DMRs from the WGBS study described above, the

second included 19,057 CpGs associated with asthma or allergic disease in 17 previous

EWAS (**Table E1** in this article's Online Repository), and the third included 570,350 CpGs

at 140 GWAS loci (**Table E2** in this article's Online Repository). We then removed CpGs

on the EPIC array, in ENCODE blacklisted regions[12], and those that overlapped with a

common SNP in 1000 Genomes European (CEU) or African (YRI) populations. In the

second step, we further prioritize the remaining 696,225 CpGs, by considering their

overlap with six functional annotations: 1) ENCODE[15] TFBSs from all cell types; 2-4)

ROADMAP Epigenetics[16] transcriptional start sites, poised enhancers and active

enhancers from smooth muscle (E078, E076, E103, E111), epithelial (E055, E056, E059,

E061, E058), and blood cells (E062, E034, E045, E044, E043, E039, E041, E042, E040,

E037, E048, E038, E047, E029, E050, E032, E046); 5) ATAC-seq in human cultured

bronchial epithelial cells exposed to rhinovirus or a vehicle control from asthmatic and

non-asthmatic individuals[17], and 6) pcHi-C from *ex vivo* human bronchial epithelial

cells[17]. We then required that CpGs within DMRs overlap with at least three annotations

or other category of prior evidence, CpGs from prior EWAS overlap with at least one

annotation or other category of prior evidence, and CpGs at GWAS loci overlap with at

least four annotation categories or other category of prior evidence. After removing

duplicates, 92,024 high-value CpGs remained and 53,700 of these CpGs were amenable

to the Illumina design algorithm. We selected 44,047 CpGs targeted by 49,999 probes

for manufacturing, of which 14% subsequently failed, resulting in a Custom array with

38,541 CpGs targeted by 43,605 probes. After removing probes with unknown origins

and those without genomic coordinates, 37,863 CpGs passed array QC. The locations of

the 37,863 CpGs, their selection among the three primary criteria, and their overlap

with the annotation categories are shown in Supplementary Dataset 1. Finally, for our

analyses we further removed probes that included a common SNP (MAF≥5%) within 3

bp of the CpG interrogation site, probes that failed the minfi QC, and probes on the X

chromosome, leaving 37,256 CpGs following both array and processing QC.

Processing Custom and EPIC array methylation data in URECA and INSPIRE

DNA methylation was assessed using the Illumina Allergy&Asthma Custom BeadChip

v1.0 or the Illumina Infinium MethylationEPIC BeadChip (Illumina, San Diego, CA)

following bisulfite conversion at the University of Chicago Genomics Facility.

Methylation data from both arrays were processed using minfi v1.29.1[18]. The

annotation and manifest packages for the Allergy&Asthma array v1.0 can be found at

https://github.com/hansenlab/IlluminaHumanMethylationAllergymanifest. The details

of our protocols for processing the DNA methylation data on each array are described in

the Online Repository.

EWAS of AS in the URECA and INSPIRE cohorts

We defined AS as the percent of positive skin prick tests (14 airborne and oral allergens

in URECA and 13 airborne allergens in INSPIRE). For each AS EWAS we used the

following models:

URECA: DNAm ~ proportion positive SPTs + sex + %epithelial cells +
$AncPCs_{1-3} + LFs_{1-n}$

INSPIRE: DNAm ~ proportion positive SPTs + sex + race/ethnicity + DNA
concentration + LFs_{1-n}

For the URECA EWAS, we included 14 and 5 latent variables for the Custom[19] and EPIC[20]

arrays, respectively, after removing technical variables (see **Table E3** in this article's

Online Repository). Cell counts (300 cells/slide) were available on each sample[21].

Because we did not have information on cell proportion or genetic ancestry for INSPIRE,

we included sex, parent-reported race/ethnicity, DNA concentration, and 21 latent

factors as covariates to adjust for cell composition, as well as other unwanted variation

in the EWAS. Analyses were performed in R (version 4.1.0) using limma v 3.50.0[22, 23]. To

control the false discovery rate, we used a q-value threshold of 0.05. To assess the

overlap of AS DMCs with allergic asthma DMCs, we tested the AS DMCs for association

with allergic asthma in URECA and INSPIRE. For these studies, we defined allergic

asthma cases as children with a diagnosis of asthma at age 10 (URECA) or age 6

(INSPIRE) <u>and</u> sensitization to at least one allergen (N=62 and 22, respectively). For

these analyses, controls were defined as children without a diagnosis of asthma (ever)

and without any positive skin prick tests (n=76 and 271, respectively). We calculated q-

values based on the 193 AS DMCs in URECA and the 85 AS DMCs in INSPIRE.

RNA-sequencing and expression Quantitative Trait Methylation (eQTM) studies in URECA

Protocols for processing samples for RNA-seq in nasal epithelial cells from the URECA

children have been described[21]. Gene expression data were available in 249 of the

children with DNA methylation data. In these samples, 15,643 genes were detected as

expressed. To test for cis associations between DNA methylation and gene expression

(eQTM studies), we used a linear model that included sex, percent epithelial cells, and

three ancestry PCs as covariates (FDR <0.05).

Results

Identifying DMRs in Whole-Genome Bisulfite Sequences

We performed WGBS in airway epithelial cell DNA from 20 African American children

(10 with allergic asthma, 10 without asthma or allergies; 11 years old) from the URECA

cohort[7] and 19 European American young adults (9 with allergic asthma, 10 without

asthma or allergies; 18-20 years old) from the COAST cohort[8]. After quality control (QC)

(see **Methods**), analyses for differentially methylated regions (DMRs) between the

asthma/allergy cases and non-asthma/non-allergy controls were performed in the

African American sample, the European American sample, and the combined sample

(see **Methods** for additional details). Overall, we identified 16,611 DMRs that included

199,473 CpGs (**Table E4** in this article's Online Repository).

Selecting High-Value CpGs for an Asthma&Allergy Custom DNA Methylation Array

Our goal was to develop a custom array with 50,000 probes for high-value CpGs that

would complement and serve as a "booster" for the EPIC array for studies of asthma

and allergic diseases, as described above in **Methods** and in the Online Repository. After

manufacture and array QC, 37,863 CpGs targeted by 42,192 probes remained (**Table E5**

in this article's Online Repository). The distributions of the 37,256 CpGs on the Custom

array and the 789,290 CpGs on the EPIC arrays that passed final QC are shown by

annotation category in **Fig. 2A**. Of note, 90% of CpGs on the Custom array overlapped

with a transcription factor binding site (TFBS), and 94% overlapped with a predicted

enhancer, compared to 56% and 54% of the EPIC array CpGs, respectively (Fisher exact

test [FET] $p<10^{-16}$ for both comparisons). Moreover, compared to EPIC CpGs, Custom

CpGs were enriched in introns (52.8% vs. 47.2%) and exons (24.0% vs. 22.1%) and

depleted in intergenic regions (23.1% vs. 30.7%) and 5'UTRs (6.8% vs. 7.4%) (FET $p<10^{-4}$

for all comparisons) (**Fig. 2B**). The CpGs on the Custom array proportionally represented

DMR-CpGs from the studies in URECA, COAST and combined analysis in WGBS and CpGs

from the three categories of prior evidence (**Fig. E2** in this article's Online Repository).

Evaluating methylation patterns of CpGs on the Custom Array

To assess the reproducibility of methylation measures of CpGs on the Custom array, we

compared methylation levels (measured as β values) in airway epithelial cell DNA in the

WGBS to the same CpGs on the Custom and the EPIC arrays for the subset of individuals

with all three (19 URECA subjects) or two (17 COAST subjects) measures. We included

CpGs with at least 10 WGBS reads that overlapped with an array CpG that passed QC.

This resulted in 502,229 CpGs for the WGBS-EPIC comparison in URECA and 24,744 and

20,861 CpGs for the WGBS-Custom array comparisons in URECA and COAST,

respectively. The β distribution plots were similar and highly correlated between CpGs

measured by both WGBS and an array (Spearman's $p<2.2\times10^{-16}$ for each) (**Fig. E3** in this

article's Online Repository). Notably, however, compared to the EPIC array, CpGs on the

Custom array were depleted for hypermethylated CpGs and enriched for intermediate

methylated (IM) CpGs (β values 20-80%).

To more broadly assess EPIC and Custom array DNA methylation patterns, we

compared the distributions of β values across different tissues using available data for

the EPIC array in DNA from airway epithelial cells (this study), airway smooth muscle

cells[24], and buccal swabs, placenta cells, and cord blood[10], and for the Custom array in

DNA from nasal epithelial cells and nasal lavage cells from URECA children, and buccal

cells, cord blood cells, or placenta tissue from infants in the VCSIP cohort[10]. The β

distributions were similar across cell sources for the EPIC array (**Fig. 3A**) but showed

varying patterns between cell types on the Custom array (**Fig. 3B**). Whereas an average

of 68% (range: 60-79%) of CpGs on the EPIC array were either hypomethylated (0-20%)

or hypermethylated (80-100%) in all six cell types, most CpGs on the Custom array (66%

in nasal epithelial cells and 52% on average across cell types) were IM CpGs with

depletions of β values between both 0-10% (24% in nasal epithelial cells and 29% on

average) and 90-100% (10% in nasal epithelial cells and 20% on average). In fact, these β

value distributions of CpGs on the EPIC array are remarkably similar to those in nine

GTEx tissues (**Fig. E4** in this article's Online Repository)[25]. To confirm that differences

between the two arrays were a result of the selection criteria used for designing the

array, we used the same criteria for the CpGs on the EPIC array. The 26,905 high-value

EPIC CpGs also showed an enrichment for IM CpGs and a depletion of both

hypomethylated and hypermethylated CpGs (**Fig. E5** in this article's Online Repository).

EWAS of Allergic Sensitization in 280 Multi-Ancestry Children using the Custom and

EPIC Arrays

Our ultimate goal was to develop a DNA methylation array that could detect asthma- or

allergy-associated differential methylation that is missed by the content on the EPIC

array. AS is an IgE response to allergens[26] and a crucial step in the development of

allergic diseases and common phenotypes of asthma[21, 27, 28]. We conducted an EWAS of

AS (see **Methods**) in airway epithelial cell DNA collected from 280 11-year old URECA

children using the Custom and the EPIC arrays. The demographic and clinical description

of the URECA children is shown in **Table I** and **Fig. E6** in this article's Online Repository.

Following QC of the array, we performed two EWAS of AS in the same URECA

children using the EPIC and Custom arrays (see **Methods**). Using a q-value threshold of

0.05, we identified 1,805 differentially methylated CpGs (DMCs) using the EPIC array and

193 DMCs using the Custom array (**Fig. 4A-B**), revealing an enrichment for AS DMCs on

the Custom compared to the EPIC array (0.50% vs. 0.23% of CpGs on each array,

respectively; FET $p<2.2x10^{-16}$). Among the DMCs on the EPIC array, 295 (16%) were

high-value EPIC CpGs, a significant enrichment compared to 3.5% of high-value CpGs

among all CpGs on the EPIC array (FET $p<2.2x10^{-16}$). In contrast to the different β

distributions of CpGs on each array (**Fig. 3A**), the β distributions of DMCs were similar

(**Fig. 4A-B**; middle panels), showing a near complete depletion of both hypomethylated

and hypermethylated CpGs and an enrichment of IM CpGs among AS DMCs in airway

epithelial cells. The DMCs on both arrays were distributed across the autosomes (**Fig.**

E7A-B in this article's Online Repository), however, Custom array DMCs showed spikes

of association signals compared to the sparse distribution of EPIC array DMCs. In fact,

50% of DMCs on the Custom array were within 100bp of the next nearest DMC

compared to only 3% of DMCs on the EPIC array (**Fig. 4D**). Regional clustering of DMCs

on the Custom array provides greater confidence in and internal validation of EWAS

results.

Most of the functional annotation categories of DMCs were proportional to all

CpGs on each array (**Fig. 2A and 2C**; see **Fig. 2** legend for all statistical test results).

However, DMCs from both arrays were depleted at transcription start sites and in areas

of open chromatin compared to all CpGs on the arrays. Among the primary criteria

(prior evidence), CpGs in DMRs were modestly enriched for DMCs compared to all CpGs

on the Custom array and DMCs in prior EWAS studies were modestly enriched on the

Custom array but significantly enriched on the EPIC array. In contrast, CpGs at GWAS loci

were not enriched among DMCs on the Custom array and only modestly enriched on

the EPIC array compared to all CpGs on the array. The genomic locations of the DMCs

were proportional to all CpGs on the arrays (**Fig. 2B and 2D**).

Because AS is an important step in the development of childhood asthma, we

next asked whether AS DMCs were also associated with allergic asthma. Considering

only the AS DMCs on the EPIC array, 1,155 (64%) were also associated with allergic

asthma at q-value <0.05 (1,805 tests). Among the AS DMCs on the Custom array, 115

(60%) were also associated with allergic asthma at q-value <0.05 (193 tests). The effect

sizes were significantly correlated between AS DMCs and allergic asthma DMCs (r=0.68).

Among the CpGs that were DMCs for both AS and allergic asthma, all showed the same

direction of effect; among all AS DMCs, 93% showed the same direction of effect with

allergic asthma (r=0.84) (**Fig. 4E**). The sample distributions of AS and allergic asthma are

shown in **Fig. E8** in this article's Online Repository.

Validating the Custom Array in the INSPIRE Cohort

The URECA cohort is diverse with respect to ancestry (**Fig. E9** in this article's Online

Repository) but includes <1% non-Hispanic White children[7]. Therefore, to both replicate

results of the EWAS in URECA children and assess the performance of the Custom array

in a primarily non-Hispanic White population, we studied 5- to 7-year-old children from

the INSPIRE cohort[9]. An EWAS was performed using the Custom array and nasal

epithelial cell DNA from 474 children with measures of AS (see **Methods**). See **Table I** for

demographic and clinical characteristics, **Fig. E6** in this article's Online Repository for

sensitization rates by allergen, and the Online Repository for details on processing and

QC of the array data.

At a q-value threshold of <0.05 (37,261 tests), 85 CpGs on the Custom array were

DMCs (0.2% of CpGs). The β distribution of the DMCs (**Fig. 4C**) and the patterns of

associations (**Fig. E7C** in this article's Online Repository) were similar to those observed

in URECA. Among the AS DMCs in INSPIRE, 38% were also allergic asthma DMCs (q-

value<0.05 based on 85 tests), all with the same direction of effect. Among all AS DMCs

in INSPIRE, 93% had the same direction of effect with allergic asthma (**Fig. 4F**).

Moreover, among the AS DMCs in URECA, 25 (13%) were also AS DMCs in INSPIRE,

which was a highly significant enrichment (p<2.2x10[-16]), and all AS DMCs had

concordant directions of effect. Finally, the effect sizes of the 253 CpGs that were DMCs

in either the URECA or INSPIRE AS EWAS were highly correlated (r=0.61; p<2.2x10[-16])

(**Fig. 4G**). The high reproducibility of EWAS results in two cohorts demonstrates that the

high-value CpGs on the Custom array identified AS DMCs that are robust to ancestry,

ascertainment strategies, age at sampling, and geography. The sample distributions of

AS and allergic asthma are shown in **Fig. E8** in this article's Online Repository.

Evaluating the Biological Significance of DMCs in Airway Epithelial Cells

Because nearly all CpGs on the Custom array were selected to overlap with a TFBS or

enhancer mark, we expected these CpGs to be correlated with the expression of genes

in airway epithelial cells more often than CpGs on the EPIC array[29]. To test this, we used

gene expression data[21] in the same cells as those used for DNA methylation studies in

249 of the URECA children and defined two sets of genes from among the 15,551 genes

detected as expressed in these cells: the nearest gene to each CpG and the promoter

capture Hi-C (pcHi-C)-defined target gene in airway epithelial cells (see **Methods**). The

latter identifies putative enhancers that physically interact with target gene promoters

and account for the 3-dimensional structure of the genome that allows for distal

regulatory elements to interact with and regulate the activity of promoters over large

distances (e.g., up to 1 Mb or more). Among the nearest expressed genes to DMCs on

the Custom (98 genes) and EPIC (1,449 genes) arrays, 63 were the nearest gene to CpGs

on both arrays. Among the pcHi-C target genes for DMCs on the Custom (245 genes) or

EPIC (1,155 genes) arrays, 95 were target genes of CpGs on both arrays. Thus, although

no CpGs overlapped between the arrays, 101 of nearest or pcHi-C target genes were

shared on both arrays (**Table E6** in this article's Online Repository). The 318 nearest or

pcHi-C target genes on the Custom array that were expressed in airway epithelial cells

were enriched in 16 pathways (FDR <0.05), including "Th1 and Th2 cell differentiation,"

"JAK-STAT signaling," "Th17 cell differentiation," and "Viral protein interaction with

cytokine and cytokine receptor" (**Table E7** in this article's Online Repository and

Supplementary Methods in the Online Repository). In contrast, the 2,366 nearest or

pcHi-C target genes on the EPIC array that were expressed in airway epithelial cells were

not enriched for any pathways (smallest FDR = 0.13). These findings further

demonstrate that the CpGs on the Custom array are enriched in pathways relevant to

asthma and allergic disease.

For each CpG-gene pair, we tested for correlation between DNA methylation and

expression levels of their nearest and pcHi-C target gene(s) to identify eQTMs.

Significantly more CpGs on the Custom array were eQTMs with their nearest gene (23%)

or pcHi-C target gene (16%) compared to CpGs on the EPIC array (11% and 9%

respectively; FET $p<2.2x10^{-16}$ in both analyses) (see the Online Repository). The high-

value EPIC CpGs were enriched for eQTMs compared to all EPIC CpGs (20% and 12%,

respectively; FET $p<2.2x10^{-16}$ in both analyses). Although more AS DMCs were eQTMs

compared to non-DMCs on both arrays, significantly more were on the Custom

compared to the EPIC array (nearest gene 35% vs. 20% [FET p = 0.0019] and pcHi-C 22%

vs 15% [FET p = 0.0082], respectively) (**Table E8** in this article's Online Repository). The β

distributions for DMCs on the Custom and EPIC arrays that were eQTMs were further

enriched for IM CpGs and depleted of CpGs at the extremes of the distribution (**Fig. 4**

and **Fig. E10** in this article's Online Repository).

Further Insights into the Epigenetic Regulation of Gene Expression at EWAS Loci

To examine the DMCs and their associations with gene expression more closely, we

generated regional association plots for the 10 most significant DMCs in the URECA

EWAS using the EPIC and Custom arrays. The 10 most significant EPIC DMCs were at 10

loci (**Fig. E11** in this article's Online Repository). Seven were "solitary" with no other

DMCs within 500kb and three had one other DMC within 6.5kb. Among the solitary

DMCs, six were high-value EPIC CpGs and all 10 were reported as DMCs in airway

epithelial cells in previous EWAS of asthma or allergic phenotypes. Six of the 10 DMCs

were within genes and four were intergenic. CpGs from the Custom array were present

in four of these regions, but none were AS DMCs. In contrast, the 10 most significant

Custom DMCs were at six loci and only two were solitary (**Fig. E12** in this article's Online

Repository). One solitary DMC in *ALOX15* was near a high-value and a non-high-value

EPIC DMC; the other solitary CpG in the *PDE6A* gene was also a DMC in the INSPIRE

EWAS. The other four loci had spikes of association, often with a combination of DMCs

from both arrays in URECA and the Custom array in both URECA and INSPIRE. Eight of

the 10 most significant DMCs were within genes; two were intergenic.

We selected three additional regions as examples of patterns of associations

(**Table E9** in this article's Online Repository). The first includes a spike of 11 Custom

array DMCs in URECA, 12 in INSPIRE and one high-value EPIC DMC in exons 2 and 3 of

the *CISH* (Cytokine Inducible SH2-Containing Protein) gene, a member of the SOCs family

of negative regulators of cytokine signaling (**Fig. 5A**). There was one nearby DMC from

the EPIC array downstream of *CISH*. The lead Custom and EPIC URECA DMCs were

eQTMs for *CISH*, with increased methylation associated with decreased gene expression

and fewer allergic sensitizations. The EPIC high-value CpG at this locus was identified in

previous asthma/allergy EWAS[30, 31], but this locus has not been associated with asthma

or allergic diseases in GWAS. *CISH* expression is induced by IL-13 in bronchial epithelial

cells and macrophages[32], and has been implicated in eosinophil physiology[33] and

eosinophilic inflammation[32]. Our studies are consistent with these findings and further

indicate that increased expression of *CISH* is associated with increased sensitization to

allergens and that the regulation of *CISH1* expression may be epigenetically mediated.

A second locus included one Custom DMC in URECA and INSPIRE, a second

Custom DMC in URECA, and one high-value EPIC DMC in an intron of *SLC22A5* (Solute

Carrier Family 22 Member 5) (**Fig. 5B**). The lead DMC was a high-value EPIC CpG, which

was also identified in prior EWAS in nasal epithelium[30, 31]. None of the DMCs were

eQTMs for *SLC22A5*, but all three were in a region that physically interacted with the

promoter of Interferon Response Factor 1 (*IRF1*), 91kb away, and were eQTMs for *IRF1*

($p=2.4 \times 10^{-7}$, beta=0.27 and $p=2.7 \times 10^{-6}$, beta=0.27). This region is at a GWAS locus for

adult- and childhood-onset asthma and hay fever[34, 35] (**Table E9** in this article's Online

Repository), possibly with sex-specific effects[36]. Genetic variation in the *IRF1* gene has

been associated with increased expression of pro-inflammatory genes and IL-13

secretion in peripheral blood cells[37]. Our studies further demonstrate long-range

epigenetic regulation of *IRF1* expression in airway epithelial cells, with increased

methylation levels associated with increased gene expression and decreased numbers

of sensitizations.

At a third locus, we observed a spike of three Custom array DMCs in URECA and two in

INSPIRE upstream of the *HDAC7* (Histone Deacetylase 7) gene (**Fig. 5C**). One Custom

DMC (upstream of *HDAC7* and downstream of *VDR*) was an eQTM for *HDAC7*. Histone

deacetylases (HDACs) have diverse functions, including regulation of inflammatory

genes[38], and impaired barrier function in asthmatics was both induced by HDAC activity

and reversed by inhibition of endogenous HDAC[39]. In this study, increased methylation

in the *HDAC7* gene was associated with increased expression of *HDAC7* and fewer

sensitizations. At this extended locus, two EPIC DMCs were in an intergenic region 42kb

upstream of the *VDR* (Vitamin D Receptor) gene. Vitamin D deficiency in childhood has

been associated with increased risk for persistent asthma[40] and high dose vitamin D

supplementation in pregnancy reduced risk of recurrent wheeze in childhood[41]. Here,

increased methylation (EPIC array) near the *VDR* gene was associated with decreased

VDR expression and sensitization to fewer allergens. The *HDAC7-VDR* region has been

identified in GWAS of childhood- and adult-onset asthma[34]. This locus demonstrates the

complementarity of the Custom and EPIC arrays in detecting differential methylation

relevant to asthma and allergic diseases.

Discussion

The epigenome plays a critical role in regulating gene expression in a context-specific manner, such as in specific cell types or in the presence of environmental exposures or disease states. DNA methylation, for example, is responsive to disease promoting exposures in both *in vitro* cell models[24, 42-44] and *ex vivo* cells from individuals who are healthy and with disease[1, 45-48]. Yet the DNA methylome has been underexplored and largely limited to the CpGs on commercial arrays. As a result, it is unknown whether the 800,000 or fewer CpGs interrogated in nearly all EWAS to date include CpGs most relevant to any specific exposure, disease, or cell type. Here, we addressed this question by designing a custom Allergy&Asthma DNAmethylation array with 37,863 high-value CpGs that are not on the commercial EPIC array. Our study design allowed us to make important observations regarding features of high-value CpGs and to propose a pipeline that can be used to prioritize CpGs from among the more than 28 million CpGs in the human genome.

Although we did not use methylation levels as a selection criterion, the CpGs selected were significantly enriched for IM CpGs (β values 20-80%). The CpGs that were DMCs and eQTMs were further enriched for IM CpGs on both the EPIC and Custom arrays, suggesting that this feature is a signature of high-value, variable and likely functional CpGs in the genome. In contrast, the non-IM CpGs may be more functionally constrained and less responsive to environmental perturbations. Our results are supported by previous WGBS studies showing that IM CpGs were more likely to be

tissue specific, to vary between individuals, and to play important roles in gene

regulation[29, 49]. Our study further revealed that CpGs with intermediate levels of

methylation are also more likely to be associated with AS, an important clinical

phenotype that reflects both an immune response to past allergen exposures[26] and a

risk factor for the development of asthma and allergic diseases[21, 27, 28]. Although the

CpGs on the custom array were overall enriched for IM CpGs, AS DMCs were further

enriched, with a depletion of very hypomethylated (0-20% methylation) and very

hypermethylated (80-100%) CpGs. This important observation was further supported by

EWAS results using the EPIC array. Whereas the EPIC array is enriched for

hypomethylated and hypermethylated CpGs in all tissues, the AS DMCs from the EPIC

were depleted for CpGs at both extremes and enriched for IM CpGs, similar to the DMCs

on the custom Allergy&Asthma array. We further showed that the 26,905 high-value

EPIC CpGs were also enriched for IM CpGs and enriched among AS DMCs: 16.3% of the

DMCs in the AS EWAS were among the high-value EPIC CpGs compared to 3.4% of all

EPIC CpGs. These results, combined with previous studies[29, 49], could justify filtering

CpGs on the EPIC array to include just IM CpGs (β=20-80%) to enrich for functional CpGs

and increase power to detect DMCs associated with exposures or disease outcomes. As

proof-of-concept, including only IM EPIC CpGs and using a q-value of 0.05, 2,182 CpGs

were AS DMCs (0.70% of all IM CpGs), more than three times the proportion of DMCs

among all CpGs (1,805 AS DMCs; 0.23% of all EPIC CpGs). Finally, DMCs that were

eQTMs were further enriched for IM CpGs (**Fig. 4** and **Fig. E10** in this article's Online

Repository), supporting their role in gene regulation.

In addition to the enrichment of IM CpGs on the Custom compared to the EPIC

array, the different patterns of associations with AS were notable. Whereas DMCs on

the EPIC were more sparsely distributed throughout the genome, the DMCs on the

Custom often showed spikes of associations, analogous to GWAS peaks. The spatial

organization among DMCs on the Custom array provides confirmatory evidence for their

veracity, which is generally not available for EPIC CpGs (**Figure 4D**). Another

distinguishing feature of the DMCs on the Custom array was their enrichment in exons

and depletions in intergenic regions compared to DMCs on the EPIC array. This is

consistent with results of an earlier study that observed enrichments of IM CpGs in

exons, where exon expression at those sites correlated with DNA methylation[29].

The CpGs included on the custom Allergy&Asthma array were selected based on

prior evidence of associations with asthma or allergic diseases using three classes of

evidence: within a DMR in our WGBS study, in a previous published EWAS, or at

published GWAS loci. Overall, 62% of CpGs on the custom array were selected from

DMRs compared to 1.6% of all CpGs on the EPIC array, yet the DMR CpGs were enriched

among DMCs on both the custom (77.2%) and EPIC (3.9%) arrays. In contrast, few

previous EWAS CpGs were on the Custom array because we excluded all CpGs on the

EPIC from the Custom array, yet we still observed a modest enrichment of EWAS CpGs

among Custom array DMCs (1.9% overall vs. 4.1% of DMCs) and a highly significant

enrichment among DMCs on the EPIC array (4.9% overall vs. 21.7% of DMCs). These

represent replications of results from previous EWAS of asthma and allergic phenotypes

in the URECA children. Surprisingly, CpGs at asthma and allergy GWAS loci were only

modestly enriched among EPIC DMCs and not at all enriched among the Custom DMCs,

even though the EWAS in URECA and INSPIRE revealed many examples of AS DMCs at

important GWAS loci. The lack of enrichment of Custom array CpGs at GWAS loci among

DMCs may reflect the less direct evidence for DNA methylation mechanisms at GWAS

loci compared to CpGs from previous EWAS or DMR studies, the large proportion of

CpGs at GWAS loci included on the Custom array (44% of all CpGs), and the enrichment

of AS DMCs among genic regions whereas GWAS loci are more often in intergenic

regions.

Our study has limitations. First, due to cost and technical limitations, the Custom

array included only 37,863 CpGs out of the 92,024 high-value CpGs that we identified

with our pipeline. Therefore, together with the 26,905 high-value EPIC CpGs, we only

surveyed 54% of potential high-value CpGs in airway epithelium that are relevant to

asthma and allergic diseases. The next generation (v1.1) of the Custom array includes

~8,000 more high-value CpGs, reducing this gap, although alternative array designs or

other methods that allow the inclusion of the 118,929 high-value CpGs would be a

powerful tool for assessing epigenetic mechanisms in these conditions. Second, we have

not yet evaluated the performance of this array in blood cells, a much more easily

sampled tissue. Those studies are currently underway. Lastly, we did not functionally

validate the correlations between CpGs and gene expression or identify the "causal"

CpG(s) driving the correlations, which should be considered in follow-up studies of any

of the EWAS regions reported here.

In summary, our study revealed high-value CpGs in airway epithelial cells that

are not interrogated on the EPIC array. The allergic sensitization EWAS revealed

potential epigenetic regulatory mechanisms both for genes previously implicated in

asthma or allergy pathogenesis but not identified in GWAS (e.g., *CISH* [32, 33], *NEDD4L* [50, 51],

PRDM10 [52, 53]) as well as for genes at replicated GWAS loci (e.g., *IRF1, CLEC16A,*

HDAC7/VDR, ALOX15, SLC22A5) (**Table E9** in this article's Online Repository). These

associations were robust to race/ethnicity, ascertainment, age, and geography. We

suggest that similar pipelines can be used to identify high-value CpGs for other disease

groups or specific environmental exposures leading to the discovery of currently

invisible portions of the epigenome that are relevant to human health.

References

1.   Prunicki M, Cauwenberghs N, Lee J, Zhou X, Movassagh H, Noth E, et al. Air pollution

exposure is linked with methylation of immunoregulatory genes, altered immune cell profiles,

and increased blood pressure in children. Sci Rep. 2021;11(1):4067.

2.   Li Y, Hamilton KJ, Wang T, Coons LA, Jefferson WN, Li R, et al. DNA methylation and

transcriptome aberrations mediated by ERalpha in mouse seminal vesicles following

developmental DES exposure. Proc Natl Acad Sci U S A. 2018;115(18):E4189-E98.

3.   Tobi EW, Slieker RC, Luijk R, Dekkers KF, Stein AD, Xu KM, et al. DNA methylation as a

mediator of the association between prenatal adversity and risk factors for metabolic disease in

adulthood. Sci Adv. 2018;4(1):eaao4364.

4.   Li M, Zou D, Li Z, Gao R, Sang J, Zhang Y, et al. EWAS Atlas: a curated knowledgebase of

epigenome-wide association studies. Nucleic Acids Res. 2019;47(D1):D983-D8.

5.   Holgate ST. The sentinel role of the airway epithelium in asthma pathogenesis. Immunol

Rev. 2011;242(1):205-19.

6.   Akdis CA. The epithelial barrier hypothesis proposes a comprehensive understanding of

the origins of allergic and other chronic noncommunicable diseases. J Allergy Clin Immunol.

2022;149(1):41-4.

7.   Gern JE, Visness CM, Gergen PJ, Wood RA, Bloomberg GR, O'Connor GT, et al. The Urban

Environment and Childhood Asthma (URECA) birth cohort study: design, methods, and study

population. BMC Pulm Med. 2009;9:17.

8.   Lemanske RF, Jr. The childhood origins of asthma (COAST) study. Pediatr Allergy

Immunol. 2002;13(s15):38-43.

9.   Larkin EK, Gebretsadik T, Moore ML, Anderson LJ, Dupont WD, Chappell JD, et al.

Objectives, design and enrollment results from the Infant Susceptibility to Pulmonary Infections

and Asthma Following RSV Exposure Study (INSPIRE). BMC Pulm Med. 2015;15:45.

10.   Shorey-Kendrick LE, McEvoy CT, O'Sullivan SM, Milner K, Vuylsteke B, Tepper RS, et al.

Impact of vitamin C supplementation on placental DNA methylation changes related to maternal

smoking: association with gene expression and respiratory outcomes. Clin Epigenetics.

2021;13(1):177.

11.   Kechin A, Boyarskikh U, Kel A, Filipenko M. cutPrimers: A New Tool for Accurate Cutting

of Primers from Reads of Targeted Next Generation Sequencing. J Comput Biol.

2017;24(11):1138-43.

12.   Krueger F, Andrews SR. Bismark: a flexible aligner and methylation caller for Bisulfite-

Seq applications. Bioinformatics. 2011;27(11):1571-2.

13.   Genomes Project C, Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, et al. A

global reference for human genetic variation. Nature. 2015;526(7571):68-74.

14.   Amemiya HM, Kundaje A, Boyle AP. The ENCODE Blacklist: Identification of Problematic

Regions of the Genome. Sci Rep. 2019;9(1):9354.

15.   Consortium EP, Moore JE, Purcaro MJ, Pratt HE, Epstein CB, Shoresh N, et al. Expanded

encyclopaedias of DNA elements in the human and mouse genomes. Nature.

2020;583(7818):699-710.

16.   Roadmap Epigenomics C, Kundaje A, Meuleman W, Ernst J, Bilenky M, Yen A, et al.

Integrative analysis of 111 reference human epigenomes. Nature. 2015;518(7539):317-30.

17.   Helling BA, Sobreira DR, Hansen GT, Sakabe NJ, Luo K, Billstrand C, et al. Altered

transcriptional and chromatin responses to rhinovirus in bronchial epithelial cells from adults

with asthma. Commun Biol. 2020;3(1):678.

18.   Aryee MJ, Jaffe AE, Corrada-Bravo H, Ladd-Acosta C, Feinberg AP, Hansen KD, et al.

Minfi: a flexible and comprehensive Bioconductor package for the analysis of Infinium DNA

methylation microarrays. Bioinformatics. 2014;30(10):1363-9.

19.   McKennan C. Factor analysis in high dimensional biological data with dependent

observations. arXiv:200911134v1. 2020.

20.   McKennan C, Nicolae DL. Accounting for unobserved covariates with varying degree of

estimability in high dimensional experimental data. Biometrika. 2019;106(4):823-40.

21.   Altman MC, Calatroni A, Ramratnam S, Jackson DJ, Presnell S, Rosasco MG, et al.

Endotype of allergic asthma with airway obstruction in urban children. J Allergy Clin Immunol.

2021.

22.   Phipson B, Lee S, Majewski IJ, Alexander WS, Smyth GK. Robust Hyperparameter

Estimation Protects against Hypervariable Genes and Improves Power to Detect Differential

Expression. Ann Appl Stat. 2016;10(2):946-63.

23.   Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential

expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res.

2015;43(7):e47.

24.   Thompson EE, Dang Q, Mitchell-Handley B, Rajendran K, Ram-Mohan S, Solway J, et al.

Cytokine-induced molecular responses in airway smooth muscle cells inform genome-wide

association studies of asthma. Genome Med. 2020;12(1):64.

25. Oliva M, Demandelis K, Jasnime F, Lu Y, Hahsan H, Kibriya M, et al. Genetic regulation of

DNA methylation across tissues reveals thousands of molecular links to complex traits. Research

Square. 2021.

26. van Ree R, Hummelshoj L, Plantinga M, Poulsen LK, Swindle E. Allergic sensitization:

host-immune factors. Clin Transl Allergy. 2014;4(1):12.

27. Illi S, von Mutius E, Lau S, Nickel R, Niggemann B, Sommerfeld C, et al. The pattern of

atopic sensitization is associated with the development of asthma in childhood. J Allergy Clin

Immunol. 2001;108(5):709-14.

28. Jackson DJ, Gern JE, Lemanske RF, Jr. The contributions of allergic sensitization and

respiratory pathogens to asthma inception. J Allergy Clin Immunol. 2016;137(3):659-65; quiz 66.

29. Elliott G, Hong C, Xing X, Zhou X, Li D, Coarfa C, et al. Intermediate DNA methylation is a

conserved signature of genome regulation. Nat Commun. 2015;6:6363.

30. Cardenas A, Sordillo JE, Rifas-Shiman SL, Chung W, Liang L, Coull BA, et al. The nasal

methylome as a biomarker of asthma and airway inflammation in children. Nat Commun.

2019;10(1):3095.

31. Forno E, Wang T, Qi C, Yan Q, Xu CJ, Boutaoui N, et al. DNA methylation in nasal

epithelium, atopy, and atopic asthma in children: a genome-wide study. Lancet Respir Med.

2019;7(4):336-46.

32. Takeshima H, Horie M, Mikami Y, Makita K, Miyashita N, Matsuzaki H, et al. CISH is a

negative regulator of IL-13-induced CCL26 production in lung fibroblasts. Allergol Int.

2019;68(1):101-9.

33.   Burnham ME, Koziol-White CJ, Esnault S, Bates ME, Evans MD, Bertics PJ, et al. Human

airway eosinophils exhibit preferential reduction in STAT signaling capacity and increased CISH

expression. J Immunol. 2013;191(6):2900-6.

34.   Pividori M, Schoettler N, Nicolae DL, Ober C, Im HK. Shared and distinct genetic risk

factors for childhood-onset and adult-onset asthma: genome-wide and transcriptome-wide

studies. Lancet Respir Med. 2019;7(6):509-22.

35.   Johansson A, Rask-Andersen M, Karlsson T, Ek WE. Genome-wide association analysis of

350 000 Caucasians from the UK Biobank identifies novel loci for asthma, hay fever and eczema.

Hum Mol Genet. 2019;28(23):4022-41.

36.   Myers RA, Scott NM, Gauderman WJ, Qiu W, Mathias RA, Romieu I, et al. Genome-wide

interaction studies reveal sex-specific asthma risk alleles. Hum Mol Genet. 2014;23(19):5251-9.

37.   Landgraf-Rauf K, Boeck A, Siemens D, Klucker E, Vogelsang V, Schmidt S, et al. IRF-1

SNPs influence the risk for childhood allergic asthma: A critical role for pro-inflammatory

immune regulation. Pediatr Allergy Immunol. 2018;29(1):34-41.

38.   Bhavsar P, Ahmad T, Adcock IM. The role of histone deacetylases in asthma and allergic

diseases. J Allergy Clin Immunol. 2008;121(3):580-4.

39.   Wawrzyniak P, Wawrzyniak M, Wanke K, Sokolowska M, Bendelja K, Ruckert B, et al.

Regulation of bronchial epithelial barrier integrity by type 2 cytokines and histone deacetylases

in asthmatic patients. J Allergy Clin Immunol. 2017;139(1):93-103.

40.   Hollams EM, Teo SM, Kusel M, Holt BJ, Holt KE, Inouye M, et al. Vitamin D over the first

decade and susceptibility to childhood allergy and asthma. J Allergy Clin Immunol.

2017;139(2):472-81 e9.

41.   Wolsk HM, Chawes BL, Litonjua AA, Hollis BW, Waage J, Stokholm J, et al. Prenatal

vitamin D supplementation reduces risk of asthma/recurrent wheeze in early childhood: A

combined analysis of two randomized controlled trials. PLoS One. 2017;12(10):e0186657.

42.   Pacis A, Tailleux L, Morin AM, Lambourne J, MacIsaac JL, Yotova V, et al. Bacterial

infection remodels the DNA methylation landscape of human dendritic cells. Genome Res.

2015;25(12):1801-11.

43.   Nicodemus-Johnson J, Naughton KA, Sudi J, Hogarth K, Naurekas ET, Nicolae DL, et al.

Genome-wide methylation study identifies an IL-13-induced epigenetic signature in asthmatic

airways. Am J Respir Crit Care Med. 2016;193(4):376-85.

44.   Soliai MM, Kato A, Helling BA, Stanhope CT, Norton JE, Naughton KA, et al. Multi-omics

colocalization with genome-wide association studies reveals a context-specific genetic

mechanism at a childhood onset asthma risk locus. Genome Med. 2021;13(1):157.

45.   Cardenas A, Fadadu RP, Van Der Laan L, Ward-Caviness C, Granger L, Diaz-Sanchez D, et

al. Controlled human exposures to diesel exhaust: a human epigenome-wide experiment of

target bronchial epithelial cells. Environ Epigenet. 2021;7(1):dvab003.

46.   Wan ES, Qiu W, Baccarelli A, Carey VJ, Bacherman H, Rennard SI, et al. Cigarette

smoking behaviors and time since quitting are associated with differential DNA methylation

across the human genome. Hum Mol Genet. 2012;21(13):3073-82.

47.   Bakulski KM, Dou J, Lin N, London SJ, Colacino JA. DNA methylation signature of smoking

in lung cancer is enriched for exposure signatures in newborn and adult blood. Sci Rep.

2019;9(1):4576.

48.   Sikdar S, Joehanes R, Joubert BR, Xu CJ, Vives-Usano M, Rezwan FI, et al. Comparison of

smoking-related DNA methylation between newborns from prenatal exposure and adults from

personal smoking. Epigenomics. 2019;11(13):1487-500.

49.   Busche S, Shao X, Caron M, Kwan T, Allum F, Cheung WA, et al. Population whole-

genome bisulfite sequencing across two tissues highlights the environment as the principal

source of human methylome variation. Genome Biol. 2015;16:290.

50.   Modena BD, Tedrow JR, Milosevic J, Bleecker ER, Meyers DA, Wu W, et al. Gene

expression in relation to exhaled nitric oxide identifies novel asthma phenotypes with unique

biomolecular pathways. Am J Respir Crit Care Med. 2014;190(12):1363-72.

51.   Yip KH, Kolesnikoff N, Hauschild N, Biggs L, Lopez AF, Galli SJ, et al. The Nedd4-2/Ndfip1

axis is a negative regulator of IgE-mediated mast cell activation. Nat Commun. 2016;7:13198.

52.   Zhang Y, Huang Y, Chen WX, Xu ZM. Identification of key genes in allergic rhinitis by

bioinformatics analysis. J Int Med Res. 2021;49(7):3000605211029521.

53.   Schlag K, Steinhilber D, Karas M, Sorg BL. Analysis of proximal ALOX5 promoter binding

proteins by quantitative proteomics. FEBS J. 2020;287(20):4481-99.

Acknowledgments

The authors wish to thank our ECHO colleagues, the medical, nursing, and program

staff, and the children and families participating in the ECHO cohorts. We also

acknowledge the contribution of the following ECHO program collaborators: ECHO

Components – Coordinating Center: Duke Clinical Research Institute, Durham, NC: Smith

PB, Newby KL.

Author Contributions: A.M., E.E.T., B.A.H. performed all data analyses; A.M., E.E.T.,

B.A.H., C.G.M., and C.O. designed the study and wrote the manuscript; P.F. oversaw the

laboratory assays; L.E.S-K., T.G., L.B.B., M.K., G.T.O., K.R.S., R.A.W., C.T.M., E.R.S., T.H.,

D.J.J., and J.E.G. provided clinical samples and information and consulted on study

design; M.C.A. provided gene expression data; K.C.B., R.A.M., and K.H. consulted on

study design. All authors read, commented on and approved the manuscript.

Data Sharing Plans

The gene expression data used this study are available on the Gene Expression Omnibus

(GEO) repository (accession number GSE145505). The DNA methylation array data used

in the EWAS study are available in GEO (accession number in progress). The whole-

genome bisulfite sequencing data are available in dbGaP (in progress).

Table I. Demographic characteristics of URECA and INSPIRE samples. Also see Fig. E6 in

this article's Online Repository for details on allergic sensitizations.

Characteristic	URECA	INSPIRE
Sample size (N)	280	474
Mean Age (range), years	11.1 (10.9-12.4)	6.3 (5.0-7.9)
Female sex	46.8%	47.0%
Ethnicity		
Non-Hispanic White	<1%	65.4%
Non-Hispanic Black	71.8%	18.1%
Hispanic	20.0%	9.5%
Other	7.9%	7.6%
Clinical Definitions		
Asthma	32.1%	9.5%
Allergic asthma	22.1%	4.6%
Allergic sensitization (≥1 +SPT)	63.2%	37.8%
Non-Allergic/Non-Asthma	27.1%	62.2%

 Figure Legends

Fig. 1. Overview of study design. (A) Whole-genome bisulfite sequencing (WGBS) and

differential methylation were performed in airway epithelial cell DNA from birth cohorts

comprised of African American children or European American young adults (half of

each with allergic asthma and half without asthma or allergies). To select CpGs for the

Custom array, we identified CpGs based on prior evidence of association with asthma or

allergic disease from three sources (see text and **Fig. E1** in this article's Online

Repository). The CpGs were then prioritized based on their overlap with functional

annotations to ultimately design a Custom array with 42,192 probes for 37,863 CpGs.

(B) Airway epithelial cell DNA was hybridized to both the Custom array and the EPIC

array, and β value distributions on the arrays were compared to the WGBS data and

across tissues using the Custom and EPIC array. **(C-D)** We validated the Custom array by

performing an EWAS of allergic sensitization (AS), examined correlations with the gene

expression in the same cells, and replicated findings in a second cohort and with allergic

asthma. **(E)** The combined results of the Custom and EPIC arrays in the discovery cohort

and of the Custom array in the replication cohort for known and novel loci were

examined in regional association plots.

Fig. 2. Proportions of Custom and EPIC CpGs by primary criteria, functional annotation

category, and genomic location. All comparisons were performed with a Fisher's Exact

Test. **(A)** Proportions of Custom CpGs that passed processing QC in URECA on each array

by three primary criteria and six functional annotation categories. CpGs on the Custom

array were significantly enriched ($p<2.2 \times 10^{-16}$) in all categories compared to the EPIC

array with the exception of prior EWAS, in which they were depleted on the Custom

compared to the EPIC ($p<2.2 \times 10^{-16}$). (**B**) The distributions of CpGs by genomic location.

Compared to the EPIC, CpGs on the Custom array were enriched in introns and exons

and depleted in intergenic regions and 5'UTRs ($p<10^{-4}$) but did not differ in any other

categories. (**C**) Proportions of Custom and EPIC differentially methylated CpGs (DMCs)

from each array by three primary criteria and six functional annotation categories.

Compared to all CpGs, DMCs from both arrays were depleted at transcription start sites

and in areas of open chromatin (Custom $p=1.14 \times 10^{-7}$ and $p=4.11 \times 10^{-9}$; EPIC $p<2.2 \times 10^{-16}$

for both, respectively). DMRs were marginally enriched for DMCs compared to all CpGs

on the Custom array ($p=0.066$) but significantly enriched on the EPIC array ($p=1.54 \times 10^{-6}$).

DMCs in prior EWAS studies of asthma and allergic diseases were modestly enriched on

the Custom array (FET $p=0.059$) and significantly enriched on the EPIC array ($p<2.2 \times 10^{-}$

^{16}). In contrast, CpGs at GWAS loci for asthma and allergic diseases were not enriched

among DMCs on the Custom array ($p=0.32$) and only modestly enriched on the EPIC

array ($p=0.042$). (**D**) The distribution of DMCs by genomic location. The distribution of

DMCs on both arrays did not differ from the distributions of all CpGs.

Fig. 3. Cross-tissue comparisons of methylation levels for CpGs on the EPIC and

Custom arrays. Density distribution plots of methylation levels, measured as β values, in

96 individuals after quantile (Custom) or quantile + SWAN (EPIC) normalizations (see

Methods). The x-axis shows the proportion of methylation at CpG sites on the EPIC (**A**)

and Custom (**B**) arrays for individuals. All DNA methylation data were processed using

the same pipeline. The nasal epithelial cell DNA (EPIC and Custom) and nasal lavage cell

DNA (Custom) are shown for the same randomly selected URECA children. The buccal,

placenta, and cord blood cells were from infants in the VCSIP Study.

Fig. 4. Allergic sensitization (AS) EWAS results in URECA and INSPIRE children using the

EPIC and Custom arrays. (A-C) Upper panel: Volcano plots showing the $\log_2$-fold change

in methylation (M-values) by proportion positive skin prick tests (x-axis) and the $-\log_{10}$(P-

value) from the EWAS (y-axis). Significant DMCs at a q-value threshold of 0.05 are shown

are shown in blue or purple (EPIC and high-value EPIC, respectively) in URECA, and

Custom in red (URECA) or turquoise (INSPIRE). The number of AS DMCs that were

hypermethylated or hypomethylated are shown as up and down arrows, respectively.

(A-C) Middle panel: Density plots of the DMC β values in each EWAS. (**A-B**) Lower panel:

Density plots of β values for DMCs that are eQTMs for their nearest genes (also see **Fig.**

E10 in this article's Online Repository). **D**) Distributions of the distances of DMCs to the

next nearest DMC on the Custom (red) and EPIC (blue) arrays. The distance to nearest

DMC is shown on the x-axis; the proportion of DMCs in each distance bin is shown on

the y-axis. (**E-F**) Correlation of effect sizes (log fold change) of AS DMCs and allergic

asthma in URECA and INSPIRE. The effect size of DMCs for AS (x-axis) and allergic

asthma (y-axis) are shown. Red or turquoise dots were associated with allergic asthma

at a q-value ≤0.05 in URECA or INSPIRE, respectively; black dots are AS-only DMCs. (**G**)

Correlation of effect sizes (log fold change) between DMCs identified in the INSPIRE AS

EWAS (x-axis) and the URECA AS EWAS (y-axis). Red or turquoise points are AS DMCs

only in URECA or INSPIRE, respectively, at a q-value threshold of 0.05; black points are

AS DMCs in both at a q-value ≤0.05. The dashed lines in E-G are the correlation lines.

Fig. 5. DMCs and eQTMs at 3 exemplary loci. In each panel, locus zoom plots show the

DMCs from the three AS EWAS using the EPIC array (URECA; blue points = non-high

value CpGs; purple point = high-value [filtered] CpGs) and Custom array (URECA, red

points; INSPIRE, turquoise points). The genomic locations and genes are shown on the x-

axis; EWAS p-values are shown on the y-axis. The dashed horizontal lines show the 0.05

q-value threshold for the Custom array in URECA (red) and for the EPIC array in URECA

and Custom array in INSPIRE (blue and purple overlaid). The bar code at the top of the

plot shows the location of CpGs at this locus on both arrays. The most significant DMC in

the region for a given EWAS (cohort and platform; see legend) is illustrated by a diamond;

additional DMCs appear as circles. Correlations between methylation levels (x-axis) of the

lead Custom and high-value EPIC CpGs in URECA and expression of relevant genes (y-

axis) in epithelial cells from URECA children are shown in the upper right of each panel,

and boxplots of the proportion of positive skin prick tests (x-axis) and methylation levels

for the lead Custom and high-value EPIC CpGs in URECA (from the EWAS) are shown in

the lower right of each panel. **A)** *CISH* locus on chromosome 3. **B)** *SLC22A5-IRF1* locus on

chromosome 5. **C)** *HDAC7-VDR* locus on chromosome 12.

Fig. 1.

Fig. 2.

Fig. 3.

8   **Fig. 4.**

Fig. 5